Drug Trial Radar · NCT07174427
Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma
Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
5
Planned (sponsor's estimate)
Start
Jan 5, 2026
Primary completion
Mar 2032
Study completion Mar 2032
Sponsor
- Lead sponsor
- Takara Bio Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to verify the safety and the efficacy of TBI-1301 for NY-ESO-1 expressing synovial sarcoma when administered following cyclophosphamide/fludarabine pre-treatment.
Conditions
- Synovial Sarcomas
Interventions
TBI-1301Biological
Split dose of TBI-1301 is administered intravenously for 2 days following cyclophosphamide/fludarabine pre-treatment.
CyclophosphamideDrug
Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.
FludarabineDrug
Fludarabine (30mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rateTime frame: 52 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Kyusyu University Hospital
Fukuoka, Japan · Recruiting
National Cancer Center Hospital East
Kashiwa, Japan · Recruiting
Osaka International Cancer Institute
Osaka, Osaka, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.